Gsa Capital Partners LLP Aravive, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 16, 2024
BUY
$0.11 - $0.22 $217,514 - $435,029
1,977,407 New
1,977,407 $237,000
Q3 2021

Nov 12, 2021
SELL
$3.67 - $5.8 $323,334 - $510,991
-88,102 Closed
0 $0
Q2 2021

Aug 05, 2021
BUY
$4.65 - $6.42 $174,779 - $241,308
37,587 Added 74.41%
88,102 $527,000
Q1 2021

May 10, 2021
BUY
$5.11 - $9.24 $258,131 - $466,758
50,515 New
50,515 $333,000

Others Institutions Holding ARAV

# of Institutions
2
Shares Held
28.1K
Call Options Held
0
Put Options Held
0
View Full List

About Aravive, Inc.

ARAV Quotes by TradingView
  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email